155388-58-2

Upstream product

• 614-75-5 2-Hydroxyphenylacetic acid 
• 67-56-1 methanol 
• 51794-07-1 2-hydroxy-5-nitrophenylacetic acid 

Downstream Products

• 912948-23-3 2-(2-Hydroxy-5-nitro-phenyl)-N-methyl-acetamide 
• 287119-96-4 methyl 2-methylsulfonyl-5-[N-methyl-N-(4-nitrobenzyloxycarbonyl)]aminophenylacetate 
• 287120-00-7 2-methylsulfonyl-5-[N-methyl-N-(4-nitrobenzyloxycarbonyl)]aminophenylacetic acid 
• 287120-12-1 N-[2-(N,N-dimethylamino)ethyl]-2-methanesulphonyl-5-[N-methyl-N-(tert-butyloxycarbonyl)]aminophenylacetamide 
• 287120-08-5 2-methanesulfonyl-5-[N-methyl-N-(tert-butyloxycarbonyl)]aminophenylacetic acid 
• 287120-04-1 methyl 2-methanesulfonyl-5-[N-methyl-N-(tert-butyloxycarbonyl)]aminophenylacetate 
• 287119-86-2 methyl 2-(N,N-dimethylaminocarbonylthio)-5-nitrophenylacetate 
• 287119-88-4 methyl 2-(methylsulphonyl)-5-nitrophenylacetate 
• 287119-92-0 methyl 2-methylsulfonyl-5-(N-methylamino)phenylacetate 
• 287119-87-3 methyl 2-(methylthio)-5-nitrophenylacetate 
• 287119-85-1 methyl 2-(N,N-dimethylaminothiocarbonyloxy)-5-nitrophenylacetate 
• 155388-85-5 2-hydroxy-5-aminophenylacetic acid methyl ester 

Relevant academic research and scientific papers

Esterification-nitration of ortho-hydroxyphenyl carboxylic acids and benzole acids with cerium(IV) ammonium nitrate (CAN)

A convenient and useful esterification was realized, and this reaction proceeded without a dehydrating reagent or water removal equipment. A series of ortho -hydroxyphenyl carboxylic acids and benzoic acids were transformed to their corresponding methyl esters under CAN/CH3OH reaction conditions. Whereas in an aprotic solvent, acetonitrile, sp3-C tethered ortho-hydroxyphenyl carboxylic acids undergo simultaneous o,p-dinitration and intramolecular esterification reactions in good yields. Also, 2-((1E)-2-nitrovinyl)-4-nitro-phenol (3e) showed selective cytotoxicities to ward MCF-7, HEP G2, and HEP 3B cell lines with IQovalues of 23.50, 7.33, and7.59ug/mL,respectively.

NPY ANTAGONISTS, PREPARATION AND USES

The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamatesf

The rates and extent of release of a series of substituted anilines from 4-nitrobenzyl carbamates, following nitro group reduction by radiolytic, enzymic and chemical methods, are reported. The yield of released anilines decreased over the pH range 4-7, b

Structure-activity relationships in a series of 5-[(2,5- dihydroxybenzyl)amino]salicylate inhibitors of EGF-receptor-associated tyrosine kinase: Importance of additional hydrophobic aromatic interactions

Potent inhibitors of EGF-dependent protein tyrosine kinase (PTK) activity were synthesized in a series of 5-[(2,5-dihydroxybenzyl)amino]salicylates. Several of these compounds inhibited EGF-dependent DNA synthesis in ER 22 cells with IC50 1 μ